A discovery by a team of researchers, led by a Geisinger professor, could produce a potential new treatment for breast cancer.
In a study published this month in Cell reports, the team used small molecules known as peptides to disrupt a complex of two proteins, RBM39 and MLL1, found in Lung cancer cells but not in normal cells.
The research team found that the abnormal interaction between RBM39 and MLL1 is necessary for breast cancer cells to multiply and survive. The team developed non-toxic peptides that prevent these proteins from interacting with breast cancer cells, altering their growth and survival.
“Because these proteins do not interact in normal cells, the peptides we developed are not harmful to them,” said Anne M. Moon, MD, Ph.D., a professor in Geisinger’s Department of Molecular and Functional Genomics and author. main study. “This offers a promise for future treatment of non-toxic cancer.”
More laboratory tests are needed before treatment can be tested in humans, Moon said.
Pavan Kumar Puvvula et al, Inhibiting an epigenomic regulatory complex RBM39 / MLL1 with dominant-negative peptides interrupts the transcription and proliferation of cancer cells Cell reports (2021). DOI: 10.1016 / j.celrep.2021.109156
Geisinger health system
CitationResearchers discovered a protein complex that promotes cancer growth (2021, June 28), recovered on June 29, 2021 at https://medicalxpress.com/news/2021-06-protein-complex-cancer-growth .html
This document is subject to copyright. Apart from any fair treatment for the purposes of private study or research, no part may be reproduced without written permission. Content is provided for informational purposes only.